Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-beta-lactamase determinants in European hospital

Emerg Infect Dis. 2004 Mar;10(3):535-8. doi: 10.3201/eid1003.020799.


Acquired metallo-beta-lactamases (MBLs) can confer broad-spectrum beta-lactam resistance (including carbapenems) not reversible by conventional beta-lactamase inhibitors and are emerging resistance determinants of remarkable clinical importance. In 2001, multidrug-resistant Pseudomonas aeruginosa carrying bla(VIM) MBL genes were found to be widespread (approximately 20% of all P. aeruginosa isolates and 70% of the carbapenem-resistant isolates) at Trieste University Hospital. Clonal diversity and heterogeneity of resistance determinants (either bla(VIM-1)-like or bla(VIM-2)-like) were detected among MBL producers. This evidence is the first that acquired MBLs can rapidly emerge and establish a condition of endemicity in certain epidemiologic settings.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carbapenems / pharmacology*
  • Drug Resistance / genetics*
  • Europe
  • Genotype
  • Humans
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / genetics*
  • Pseudomonas aeruginosa / isolation & purification
  • Random Amplified Polymorphic DNA Technique
  • beta-Lactam Resistance / drug effects
  • beta-Lactam Resistance / genetics*


  • Carbapenems